

eTable 1. Methods of studies on mobile phone use and tumor risk.

Reference	Geog. Location	Period of case ascertain.	Age Range	Hospital or population based	Tumors considered & whether histol; grade; lobe covered	Reported response rate		% proxy interviews	% exposed among controls	Comments
						Cases	Controls			
<u>US Studies</u>										
Dreyer et al. 1999 ¹⁵	USA	1994	20+	Population	Total mortality					Cohort based on operator data. Follow up to Rothman 1996. Subjects using handheld phones compared to subjects using bag phones.
Muscat et al. 2000 ¹³ Muscat et al. 2002 ¹⁶	USA	1994-1998	18-80	Hospital	Malignant brain tumours (ICD9-CM codes 191.0-191.9) Lobe Grade Acoustic neuroma	75%	90%	9% brain tumor cases 1.1% AN cases 1.4% controls	18% brain tumor controls 27% AN controls (ever had a mobile phone subscription)	Data collection through personal interviews.
Inskip et al. 2001 ⁷	USA	1994-1998	18+	Hospital	Glioma, Meningioma, Acoustic neuroma Grade Lobe (ICD & morphology codes in paper)	92%	86%	16% glioma 8% meningioma 3% AN 3% controls	22% (regular use, i.e. at least twice per week) 45% (ever use)	Data collection through personal interviews.
Warren et al. 2003 ¹⁷	USA	1995-2000	Not stated	Hospital	Facial nerve Acoustic neuroma	Not stated	Not stated	0%	38% (ever use)	Data collection through telephone interviews.

Hardell Studies										
Hardell et al. 1999 ^{21,28}	Sweden	1994-1996	20-80	Population	All brain tumors Malign+Benign Acoustic neuroma Grade Lobe	90%	91%	Deaths excluded	38% (at least 8 hours of use)	Response proportions exclude deaths, physician refusals from denominator in all Hardell studies. Data collection through postal questionnaires.
Hardell et al. 2002 ^{20,27}	Sweden	1997-2000	20-80	Population	All brain tumors Malign+Benign Acoustic neuroma Grade Lobe	88%	91%	Deaths excluded	Analogue 15% Digital 30% Cordless 27% (ever use)	Repeated interviews of selected subjects; Data collection through postal questionnaires.
Hardell et al. 2005 ¹⁸ Hardell et al. 2006 ¹⁹	Sweden	2000-2003	20-80	Population	Benign brain tumors Acoustic neuroma Meningioma Lobes Malignant brain tumors High grade astrocytomas	89% benign 88% malign	84%	Deaths excluded	Analogue 11% Digital 50% Cordless 44% Any type 66% (ever use)	Data collection through postal questionnaires.
Hardell et al. 2004 ²²	Sweden	1994-2000	21-80	Population	Salivary gland Also by localization and histopathology	91%	90%	Deaths excluded	Analogue 13% Digital 16% Cordless 19% Any type 33% (ever use)	Majority of controls from a 2002 brain tumor study Data collection through postal questionnaires.
Hardell et al. 2005 ²³	Sweden	1999-2002	18-74	Population	Non Hodgkin Lymphoma B-cell T-cell (further subdivided) Other	91%	92%	Deaths excluded	Analogue 18% Digital 55% Cordless 41% Any type 68% (ever use)	Controls recruited on "several occasions", 30 cases excluded after ascertainment of exposure as NLH not confirmed Data collection through

										postal questionnaires.
Hardell et al. 2007 ²⁴	Sweden	1993-1997	20-75	Population	Testicular cancer Seminoma Non-seminoma	91%	89%	Deaths excluded	Analogue 20% Digital 16% Cordless 19% (ever use)	Data collection through postal questionnaires.
Hardell pooled analyses										
Hardell et al. 2006 ²⁶ Hardell et al. 2006 ²⁵	Sweden	1997-2003	20-80	Population	Benign brain tumors Acoustic neuroma Meningioma Malignant brain tumors High grade astrocytomas			Deaths excluded		Pooled analysis of Hardell 2002 ¹⁷ and 2005 ¹⁵ /2006 ¹⁶ No heterogeneity tests reported
<u>Interphone studies</u>										
Christensen et al. 2004 ³⁰ Christensen et al. 2005 ²⁹	Denmark	2000-2002	20-69	Population	Acoustic neuroma Meningioma Glioma Low grade, High grade (ICD & morphology codes in paper)	82% 71% 74%	64%	0% 2% 8%	46% 42% 50% (regular use=at least once per week during 6 months or more)	Proportion of regular use among controls reflects age and sex distribution of cases. Data collection through personal interviews.
Lonn et al. 2004 ⁸ Lonn et al. 2005 ¹²	Sweden	1999-2002 2000-2002	20-69	Population	Acoustic neuroma Meningioma Glioma Low grade, High grade Lobes (ICD & morphology codes in paper)	93% 84% 75%	72% 71%	0% 3% 9%	59% (regular use)	Data collection through personal interviews.

Schlehofer et al. 2007 ³³ Schuz et al. 2006 ³⁴	Germany	2001-2003	30-69	Population	Acoustic neuroma Meningioma Glioma Low grade, High grade	89% 88% 80%	55% in AN study 63% in brain tumor study	0% 1% 11%	38% 37% 39% (regular use)	Data collection through personal interviews.
Klaeboe et al. 2007 ³²	Norway	2001-2002	19-69	Population	Acoustic neuroma Meningioma Glioma	68% 71% 77%	69%	0% 0% 36%	63% (regular use)	Data collection through personal interviews. Large proportion of interviews was made over the phone.
Takebayashi et al. 2006 ⁹ Takebayashi et al. 2008 ³⁵	Japan	2000-2004	30-69	Hospital cases Population controls	Acoustic neuroma Meningioma Glioma Pituitary adenoma (ICD & morph- ology codes in paper)	84% 78% 59% 76%	52% 52% 53% 49%	0%	58% 52% 65% 65% (regular use)	Some hospitals did not participate. Controls selected through random digit dialing. Data collection through personal interviews.
Hepworth et al. 2006 ³¹	UK	2000-2004	18-69	Population	Glioma Low grade, High grade (ICD & morph- ology codes in paper)	51%	45%	7% cases	52% (regular use)	Study includes data from two centers in the UK. Data collection through personal interviews.
Hours et al. 2007 ³⁸	France	2001-2003	30-59	Hospital cases Population controls	Meningioma Glioma AN	60% 78% 81%	75%	4% cases	56% (regular use)	Some hospitals did not participate. Data collection through personal interviews.
Lonn et al. 2006 ³⁷	Denmark and Sweden	2000-2002	20-69	Population (malignant cases and all controls) Hospital	Malignant parotid gland Benign pleomorphic adenoma	85% (Malig n) 88% (Benig n)	60% (Denmar k) 72% (Sweden)	1 Malign case in Sweden	60% (regular use)	Matched controls in Denmark Results presented for two countries combined Data collection through

				cases (benign cases)						personal interviews.
Sadetzki et al. 2008 ³⁶	Israel	2001-2003	18-59	Population	Malignant and benign parotid gland histologically or cytologically confirmed	84% (Malign) 87% (Benign)	66%	4% cases 0.1 % controls	55% (regular use)	Data collection through personal interviews.
Interphone pooled analyses										
Schoemaker et al. 2005 ⁴¹	Denmark Finland Norway Sweden UK-South UK-North	1999-2004	18-69	Population	Acoustic neuroma	83% (69-91)	51% (42-69)	0%	54% (regular use)	Age range varied by country. Pooled analysis of six Interphone studies, includes Christensen 2004 ²⁷ , Lonn 2004 ⁸ , Klaeboe 2007 ²⁹ , and data from Finland and the UK not previously published
Lahkola et al. 2007 ³⁹ Lahkola et al. 2008 ⁴⁰	Denmark Finland Norway Sweden UK-South	2000-2004	18-69	Population	Meningioma Glioma Glioblastoma (ICD & morph- ology codes in paper)	60% (37-81) glioma 74% (55-90) mening ioma	50% (42-69)	12% of glioma cases 1.6% of meningioma 0.1% of controls	59% (regular use) 92% (ever use)	Pooled analysis of five Interphone studies, includes Christensen 2005 ²⁶ , Lonn 2005 ¹² and Klaeboe 2007 ²⁹ , part of Hepworth 2006 ²⁸ , and data from Finland not previously published
<u>Subscriber list based studies and Other Studies</u>										
Auvinen et al. 2002 ¹¹	Finland	1996	20-69	Population	All BT Glioma,				11% (ever had a	Exposure assessment based on operator data

					Meningioma, Salivary gland Microscop Lobe				mobile phone subscription)	in case-control design
Schuz et al. 2006 ⁴³ Johansen et al. 2001 ⁴²	Denmark	1982-2002	18-	Population	All cancer Brain Meningioma Glioma Acoustic neuroma Salivary gland Eye, leukemia, testis Lobes				Cohort study	Exposed cohort: mobile phone subscribers. Compared to sex-, age-, and calendar year specific cancer incidence in the general Danish population. Originally published by Johansen 2001, longer follow-up analysed in Schuz 2006.
Stang et al. 2001 ⁴⁴	Germany	1995-1998	35-74	Part- hospital Part-pop.	Uveal melanoma	84% pop. 88% hosp.	48% pop. 79% hosp.	0%	<10%	

eTable 2. Results of studies on mobile phone use and risk of glioma

Reference	Diagnostic group	No. cases ever/never user	No. controls ever/never user	OR ever* cf never (95% CI) user	OR (95% CI) for max yrs exp. (cut point)	OR (95% CI) for max cumulative exposure	OR for ever-analogue use OR (95% CI)	Laterality (ever/never) ipsi/contra
<u>US Studies</u>								
Dreyer et al. 1999 ¹⁵	Brain	2/4		No excess Too small numbers for analysis				
Muscat et al. 2000 ¹³	Non-meningioma brain (mainly malignant)	66/403	76/346	0.7 (0.5-1.1)	0.7 (0.4-1.4) (≥ 4)	0.7 (0.3-1.4) (>480 hrs)		
	Astrocytic	41/313		0.8 (0.5-1.2)				
Inskip et al. 2001 ⁷	Glioma	201/285	358/440	1.0 (0.7-1.4)	0.6 (0.3-1.4) (≥ 5)	0.5 (0.2-1.3) (>500h)		Inskip method: RR=0.9, p=0.77
<u>Hardell Studies</u>								
Hardell et al. 1999 ²¹ /2001 ²⁸	All brain	78/131	161/264	1.0 (0.7-1.4)	1.2 (0.6-2.6) (>10)	1.1 (0.3-3.4) (>968h)	0.9 (0.6-1.4)	1.1 (0.6-1.8)/ 0.7 (0.4-1.2)
	Astrocyt/glioblast	36/58		1.1 (0.6-1.8)				
Hardell et al. 2002 ^{20,27}	All malignant	79 analogue 112 digital	70 analogue 99 digital	1.1 (0.8-1.6) 1.1 (0.9-1.5)	1.2 (0.8-1.8) 1.7 (0.7-4.3) (>6)		1.1 (0.8-1.6)	1.9 (1.2-3.0)/ 0.6 (0.4-1.1) (Analogue)
	Astrocytoma low grade	12 analogue 16 digital	8 analogue 19 digital	1.2 (0.8-1.9) 1.2 (0.8-1.8)				1.6 (1.1-2.4)/ 0.9 (0.5-1.4) (Digital)
	Astrocytoma high grade	46 analogue 64 digital ? unexposed	37 analogue 52 digital ? unexposed	1.5 (0.6-3.7) 0.8 (0.4-1.6)				
Hardell et al. 2006 ¹⁹	All malignant	68 analogue	79 analogue	2.6 (1.5-4.3)	3.5 (2.0-6.4)	4.0 (2.2-7.3)	2.6 (1.5-4.3)	3.1 (1.6-6.2)/

		198 digital 63 unexp.	343 digital ? unexp.	1.9 (1.3-2.7)	3.6 (1.7-7.5)	2.4 (1.6-3.7)		2.6 (1.3-5.4)
	Astrocytoma low grade	5 analogue 24 digital 7 unexposed		1.2 (0.3-4.9) 1.4 (0.5-3.8)	1.2 (0.2-7.7) 1.5 (0.1-15)	1.4 (0.3-7.2) 1.8 (0.6-5.5)	1.2 (0.3-4.9)	2.3 (0.4-14)/ 0.3 (0.0-3.7)
	Astrocytoma high grade	52 analogue 129 digital 43 unexposed		3.6 (1.9-6.5) 2.2 (1.4-3.3)	4.7 (2.4-9.2) 4.5 (2.0-10) (>10)	5.7 (2.8-11) 2.7 (1.6-4.5) (>80h analogue >64h digital)	3.6 (1.9-6.5)	4.2 (1.9-9.4)/ 5.4 (2.2-13) (Analogue, similar pattern for digital)
Hardell pooled analysis								
Hardell et al. 2006 ²⁵	All malignant	178 analogue 402 digital 322 unexp.	297 analogue 776 digital ? unexp.	1.5 (1.1-1.9) 1.3 (1.1-1.6)	2.4 (1.6-3.4) 2.8 (1.4-5.7)	5.9 (2.5-14) 3.7 (1.7-7.7) (>2000h)	1.5 (1.1-1.9)	2.1 (1.5-2.9)/ 1.1 (0.8-1.6)
	Astrocytoma low grade	5 analogue 24 digital 7 unexposed		1.2 (0.6-2.2) 1.4 (0.9-2.3)	1.6 (0.6-4.1) 1.3 (0.2-11)		1.2 (0.6-2.2)	1.8 (1.4-2.4)/ 1.0 (0.7-1.3)
	Astrocytoma high grade	52 analogue 129 digital 43 unexposed		1.7 (1.3-2.3) 1.5 (1.2-1.9)	2.7 (1.8-4.2) 3.8 (1.8-8.1) (>10)		1.7 (1.3-2.3)	(Analogue, similar pattern for digital)
Interphone Studies								
Christensen et al. 2005 ²⁹	Low grade glioma High grade glioma	47/34 59/112	90/65 155/175	1.1 (0.6-2.0) 0.6 (0.4-0.9)	1.6 (0.4-6.1) 0.5 (0.2-1.3) (≥10)	1.2 (0.5-3.1) 0.5 (0.3-1.1) (>467.9h)		
Lonn et al. 2005 ¹²	Glioma Low grade glioma High grade glioma	214/157 44/29 155/117	399/275	0.8 (0.6-1.0) 0.6 (0.3-1.0) 0.9 (0.6-1.2)	0.9 (0.5-1.5) 1.0 (0.4-2.8) 0.8 (0.4-1.5) (≥10)	0.6 (0.4-1.0) 0.5 (0.2-1.1) 0.7 (0.4-1.1) (≥500h,	0.8 (0.5-1.2)	1.1 (0.8-1.5)/ 0.7 (0.5-1.0)

						handsfree adjusted)		
Schuz et al. 2006 ³⁴	Glioma	138/ 228	283/449	1.0 (0.7-1.3)	2.2 (0.9-5.1) (≥10)	1.0 (0.6-1.6) (>195h)		
Hepworth et al. 2006 ³¹	Glioma	508/456	898/818	0.9 (0.8-1.1)	0.9 (0.6-1.3) (≥10)	0.9 (0.7-1.2) (>544h)	0.9 (0.7-1.2)	1.2 (1.0-1.5)/ 0.8 (0.6-0.9)
Klaeboe et al. 2007 ³²	Glioma	161/128	227/131	0.6 (0.4-0.9)	0.8 (0.5-1.2) (≥6)	0.7 (0.4-1.3) (≥425h, handsfree adjusted)	0.7 (0.4-1.1)	1.0 (0.7-1.4)/ 0.7 (0.5-1.1)
Hours et al. 2007 ³⁸	Glioma	59/37	54/42	1.2 (0.7-2.1)	2.0 (0.7-5.2) (≥3.8)	1.8 (0.7-4.3) (≥260h)		1.2 (0.6-2.4)/ 1.2 (0.5-2.7)
Takebayashi et al. 2008 ³⁵	Glioma	56/27	106/57	1.2 (0.6-2.4)	0.6 (0.2-1.8) (>6.5)	1.7 (0.7-4.3) (>620h)	0.8 (0.2-3.0)	1.2 (0.7-2.3)/ 1.1 (0.6-2.0)
Interphone pooled analysis								
Lahkola et al. 2007 ³⁹	Glioma Glioblastoma	867/629 368/330	1853/1281	0.8 (0.7-0.9) 0.8 (0.6-0.9)	0.95 (0.7-1.2) 0.9 (0.6-1.2) (≥10)	0.9 (0.7-1.1) 0.9 (0.6-1.1) (>503h, handsfree adjusted)	0.9 (0.7-1.1)	1.1 (1.0-1.3)/ 0.8 (0.6-0.9)
<u>Subscriber list based Studies</u>								
Auvinen et al. 2002 ¹¹	Glioma	36/360	119/1859	1.5 (1.0-2.4)	1.7 (0.9-3.5) (>2)		2.1 (1.3-3.4)	
Schuz et al. 2006 ⁴³	Nervous system Glioma	580 257		1.0 (0.9-1.0) 1.0 (0.9-1.1)	0.7 (0.4-1.0) (≥10)			

eTable 3. Results of studies on mobile phone use and risk of meningioma

Reference	Diagnostic group	No. cases ever/never user	No. controls ever/never user	OR ever* cf never (95% CI) user	OR (95% CI) for max yrs exp. (cut point)	OR (95% CI) for max cumulative exposure	OR for ever-analogue use OR (95% CI)	Laterality (ever/never) ipsi/contra
<u>US Studies</u>								
Inskip et al. 2001 ⁷	Meningioma	67/130	358/440	0.8 (0.5-1.2)	0.9 (0.3-2.7) (≥5)	0.7 (0.2-2.4) (>500h)		Inskip method: RR=0.9, p=1.0
<u>Hardell Studies</u>								
Hardell et al. 1999 ²¹	Meningioma	16/30	161/264	1.1 (0.5-2.3)				
Hardell et al. 2002 ²⁰	Meningioma	60 analogue 78 digital ? unexposed	56 analogue 102 digital ? unexposed	1.1 (0.7-1.5) 0.8 (0.6-1.0)			1.1 (0.7-1.5)	
Hardell et al. 2005 ¹⁸	Meningioma	35 analogue 151 digital 103 unexposed	79 analogue 343 digital ? unexposed	1.7 (1.0-3.0) 1.3 (0.9-1.9)	2.1 (1.1-4.3) 1.5 (0.6-3.9) (>10)	2.9 (1.1-8.1) 1.5 (0.6-3.9) (>80h analogue >64h digital)	1.7 (1.0-3.0)	1.6 (0.7-3.9)/ 2.6 (1.1-6.0) (analogue) 1.5 (0.9-2.5)/ 1.5 (0.9-2.3) (digital)
Hardell pooled analysis								
Hardell et al. 2006 ²⁶	Meningioma	113 analogue 295 digital 455 unexposed	297 analogue 776 digital ? unexposed.	1.3 (1.0-1.7) 1.1 (0.9-1.3)	1.6 (1.0-2.5) 1.3 (0.5-3.2) (>10)	1.4 (0.5-3.8) 0.7 (0.3-1.4) (>1000h)	1.3 (1.0-1.7)	1.3 (0.9-2.0)/ 1.2 (0.7-1.8) (analogue) 1.4 (1.0-1.8)/ 1.1 (0.8-1.5) (digital)

<u>Interphone Studies</u>								
Christensen et al. 2005 ²⁹	Meningioma	67/108	133/183	0.8 (0.5-1.3)	1.0 (0.3-3.2) (≥10)	0.6 (0.3-1.6) (>467.9h)	0.8 (0.5-1.3)	
Lonn et al. 2005 ¹²	Meningioma	118/155	399/275	0.7 (0.5-0.9)	0.9 (0.4-1.9) (≥10)	0.7 (0.4-1.2) (≥500h, handsfree adjusted)	0.7 (0.4-1.3)	0.8 (0.5-1.1)/ 0.6 (0.4-0.9)
Schuz et al. 2006 ³⁴	Meningioma	104/277	234/528	0.8 (0.6-1.1)	1.1 (0.4-3.4) (≥10)	1.0 (0.6-1.8) (>195h)		
Klaeboe et al. 2007 ³²	Meningioma	96/111	227/131	0.8 (0.5-1.1)	1.0 (0.6-1.8) (≥6)	0.9 (0.4-1.7) (≥425h, handsfree adjusted)	1.2 (0.7-2.3)	0.9 (0.6-1.3)/ 0.9 (0.6-1.3)
Hours et al. 2007 ³⁸	Meningioma	71/74	80/65	0.7 (0.4-1.3)	0.7 (0.3-1.9) (≥3.8)	0.8 (0.3-2.1) (≥260h)		0.9 (0.4-1.8)/ 0.7 (0.3-1.3)
Takebayashi et al. 2008 ³⁵	Meningioma	55/73	118/111	0.7 (0.4-1.2)	1.1 (0.5-2.1) (>5.2)	0.9 (0.4-2.0) (>260h)	1.1 (0.4-3.1)	1.1 (0.7-2.0)/ 0.7 (0.4-1.1)
<u>Interphone pooled analysis</u>								
Lahkola et al. 2007 ⁴⁰	Meningioma	573/631	1696/1249	0.8 (0.7-0.9)	0.9 (0.7-1.3) (≥10)	0.9 (0.7-1.1) (>514h, handsfree adjusted)	0.8 (0.6-1.0)	0.8 (0.7-1.0)/ 0.7 (0.5-0.8)
<u>Subscriber list Studies</u>								
Auvinen et al. 2002 ¹¹	Meningioma	11/247	48/1238	1.1 (0.5-2.4)	0.8 (0.2-3.5) (>2)		1.5 (0.6-3.5)	
Schuz et al. 2006 ⁴³	Meningioma	68		0.9 (0.7-1.1)				

eTable 4. Results of studies on mobile phone use and risk of acoustic neuroma

Reference	Diagnostic group	No. cases ever/never user	No. controls ever/never user	OR ever* cf never (95% CI) user	OR (95% CI) for max yrs exp. (cut point)	OR (95% CI) for max cumulative exposure	OR for ever- analogue use OR (95% CI)	Laterality (ever/never) ipsi/contra
<u>US Studies</u>								
Muscat et al. 2002 ¹⁶	AN	18/72	23/63	0.8 (0.4-1.7)*	1.7 (0.5-5.1) (3-6)	0.7 (0.2-2.6) (>60 hrs)		Inskip method: RR=0.9, p=0.07
Inskip et al. 2001 ⁷	AN	40/56	358/440	0.8 (0.5-1.4)	1.9 (0.6-5.9) (≥5)	1.4 (0.6-3.4) (>100h)		Inskip method: RR=0.9, p=0.63
Warren et al. 2003 ¹⁷	AN	21/30	53/88	1.2 (0.6-2.2)				
<u>Hardell Studies</u>								
Hardell et al. 1999 ²¹	AN	5/8		0.8 (0.1-4.2)				
Hardell et al. 2002 ²⁰	AN	38 analogue 23 digital ? unexposed	11 analogue 19 digital ? unexposed	3.5 (1.8-6.8) 1.2 (0.7-2.2)	3.5 (0.7-16.8) 2.0 (0.2-22.1) (>10 analogue) (>5 digital)		3.5 (1.8-6.8)	
Hardell et al. 2005 ¹⁸	AN	20 analogue 53 digital 18 unexp.	79 analogue 343 digital ? unexp.	4.2 (1.8-10) 2.0 (1.1-3.8)	2.6 (0.9-8.0) 2.7 (1.3-5.7) (>10 analogue) (>5-10 digital)	6.0 (2.2-17) 2.5 (1.2-5.2) (>80h analogue >64h digital)	4.2 (1.8-10)	5.1 (1.9-14)/ 4.9 (1.2-21) (analogue) 2.9 (1.4-6.1)/ 1.6 (0.7-3.7) (digital)
Hardell pooled analysis								

Hardell et al. 2006 ²⁶	AN	68 analogue 105 digital 88 unexposed	297 analogue 776 digital ? unexp.	2.9 (2.0-4.3) 1.5 (1.1-2.1)	3.1 (1.7-5.7) 1.8 (1.1-3.0) (>10 analogue) (>5-10 digital)	5.1 (1.9-14) 3.1 (1.5-6.4) (>1000h)	2.9 (2.0-4.3)	3.0 (1.9-5.0)/ 2.4 (1.4-4.2) (analogue) 1.7 (1.1-2.6)/ 1.3 (0.8-2.0) (digital)
Interphone Studies								
Christensen et al. 2005 ³⁰	AN	45/61	97/115	0.9 (0.5-1.6)	0.2 (0.0-1.1) (≥10)	0.7 (0.3-1.7) (>467.9h)	0.3 (0.1-0.8)	
Lonn et al. 2005 ⁸	AN	89/59	356/248	1.0 (0.6-1.5)	1.9 (0.9-4.1) (≥10)	1.1 (0.6-2.1) (≥450h, handsfree adjusted)	1.6 (0.9-2.8)	1.1 (0.7-1.6)/ 0.9 (0.6-1.4)
Schlehofer et al. 2006 ³³	AN	29/68	74/120	0.7 (0.4-1.2)	0.5 (0.2-1.3) (5-9)	0.4 (0.1-1.0) (>195h)		
Klaeboe et al. 2007 ³²	AN	22/23	227/131	0.5 (0.2-1.0)	0.5 (0.2-1.4) (≥6)	0.5 (0.2-1.6) (≥425h, handsfree adjusted)	0.8 (0.3-2.2)	0.7 (0.3-1.4)/ 0.9 (0.5-1.9)
Hours et al. 2007 ³⁸	AN	58/51	123/91	0.9 (0.5-1.6)	0.7 (0.3-1.6) (≥3.8)	0.9 (0.4-2.1) (≥260h)		0.6 (0.3-1.2)/ 1.2 (0.6-2.4)
Takebayashi et al. 2006 ⁹	AN	51/46	192/138	0.7 (0.4-1.2)	0.8 (0.2-2.7) (>8)	0.7 (0.3-1.8) (>900h)	1.2 (0.4-3.8)	0.9 (0.5-1.6)/ 0.9 (0.6-1.6)
Interphone pooled analysis								
Schoemaker et al. 2005 ⁴¹	AN	360/316	1934/1612	0.9 (0.7-1.1)	1.0 (0.7-1.5) (≥10)	0.9 (0.7-1.2) (>534h)	0.9 (0.7-1.2)	0.9 (0.7-1.1)/ 1.1 (0.9-1.4)

Subscriber list based Studies

Schuz et al. 2006 ⁴³	Nerve sheath tumours, cranial nerves	32		0.7 (0.5-1.0)				
---------------------------------	--------------------------------------	----	--	---------------	--	--	--	--

* Pooling of categorical analyses

eTable 5. Results of studies on mobile phone use and risk of other tumors

Reference	Diagnostic group	No. cases ever/never user	No. controls ever/never user	OR ever* cf never (95% CI) user	OR (95% CI) for max yrs exp. (cut point)	OR (95% CI) for max cumulative exposure	OR for ever-analogue use OR (95% CI)	Laterality (ever/never) ipsi/contra
<u>Hardell Studies</u>								
Hardell et al. 2004 ²²	Salivary gland	31 analogue 45 digital ? unexposed	137 analogue 170 digital ? unexposed	0.9 (0.6-1.4) 1.0 (0.7-1.5)	0.7 (0.3-1.7) 1.2 (0.5-2.8) (>10 analogue, >5 digital)		0.9 (0.6-1.4)	
Hardell et al. 2005 ²³	B-cell	141 analogue 422 digital 278 unexposed	178 analogue 559 digital 321 unexposed	0.9 (0.7-1.3) 1.0 (0.8-1.3)	1.0 (0.7-1.4) 1.1 (0.4-3.4)	1.1 (0.7-1.6) 1.1 (0.8-1.5)	0.9 (0.7-1.3)	
	T-cell	14 analogue 31 digital 13 unexposed		1.6 (0.6-3.8) 1.4 (0.7-2.9)	1.5 (0.5-4.3) 3.0 (0.3-34.1) (>10)	1.3 (0.4-3.9) 1.5 (0.6-3.5) (>198h analogue >91h digital)	1.6 (0.6-3.8)	
Hardell et al. 2007 ²⁴	Testicular cancer	175 analogue 164 digital 515 unexposed	173 analogue 137 digital ? unexposed	1.0 (0.8-1.3) 1.1 (0.8-1.5)	2.1 (0.7-6.2) 2.8 (0.8-11) (>10 analogue, >5 digital)	0.7 (0.5-1.0) 0.9 (0.6-1.3) (>160h analogue >182h digital)	1.0 (0.8-1.3)	
<u>Interphone Studies</u>								
Lonn et al. 2006 ³⁷	Parotid, malignant Parotid, benign	25/35 77/35	401/280 202/119	0.7 (0.4-1.3) 0.9 (0.5-1.5)	0.4 (0.1-2.6) 1.4 (0.5-3.9) ≥10	0.6 (0.2-1.8) 1.0 (0.5-2.1) ≥450 hours		1.2 (0.6-2.6)/ 0.5 (0.2-1.1) 1.4 (0.9-2.2)/ 0.7 (0.4-1.1)

Sadetzki et al. 2008 ³⁶	Parotid, malignant Parotid, benign	33/25 252/150	88/106 603/469	1.1 (0.5-2.1) 0.9 (0.6-1.1)	0.5 (0.1-4.5) 0.9 (0.4-2.0) (≥10)	1.2 (0.4-3.5) 1.1 (0.7-1.6) (≥1035 hours)		1.0 (0.8-1.4)/ 0.9 (0.6-1.2) (malign&benign)
Takebayashi et al. 2008 ³⁵	Pituitary adenoma	62/39	105/56	0.9 (0.5-1.6)	0.8 (0.3-1.8) (>7.2)	1.3 (0.6-3.1) (>560h)	0.5 (0.2-1.8)	1.1 (0.7-2.0)/ 0.7 (0.4-1.1)
<u>Subscriber list based Studies and Other Studies</u>								
Auvinen et al. 2002 ¹¹	Salivary gland	4/64	18/322	1.3 (0.4-4.7)	2.3 (0.2-25.3) (>2)		1.0 (0.3-4.0)	
Schuz et al. 2006 ⁴³	Salivary Eye Leukaemia Testis	26 42 351 522		0.9 (0.6-1.3) 1.0 (0.7-1.3)* 1.0 (0.9-1.1)* 1.1 (1.0-1.2)*	1.1 (0.7-1.5) (≥10, Leukemia)			
Stang et al. 2001 ⁴⁴	Uveal melanoma			4.2 (1.2-14.5) (ever = probable/ certain use at workplace for at least several hours per day!)				

* Pooled results for men and women